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ABSTRACT
Conventional alginate pellets underwent rapid drug dissolution and failed to exert 
colon targeting unless subjected to complex coating. This study designed coatless 
delayed-release oral colon-specific alginate pellets for ulcerative colitis treatment. 
Alginate pellets, formulated with water-insoluble ethylcellulose and various calcium 
salts, were prepared using solvent-free melt pelletization technique which prevented 
reaction between processing materials during agglomeration and allowed such 
reaction to occur only in dissolution. Combination o f acid-soluble calcium carbonate 
and highly water-soluble calcium acetate did not impart colon-specific characteristics 
to pellets due to pore formation in fragmented matrices. Combination o f moderately 
water-soluble calcium phosphate and calcium acetate delayed drug release due to 
rapid alginate crosslinking by soluble calcium from acetate salt followed by sustaining 
alginate crosslinking by calcium phosphate. The use o f 1:3 ethylcellulose-to-alginate 
enhanced the sustained drug release attribute. The ethylcellulose was able to maintain 
the pellet integrity without calcium acetate. Using hydrophobic prednisolone as 
therapeutic, hydrophilic alginate pellets formulated with hydrophobic ethylcellulose 
and moderately polar calcium phosphate exhibited colon-specific in vitro drug release 
and in vivo anti-inflammatory action. Coatless oral colon-specific alginate pellets 
canbe designed through optimal formulation with melt pelletization as the processing 
technology.
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CHAPTER ONE 
INTRODUCTION
1.1 BACKGROUND OF STUDY
Inflammatory bowel disease such as ulcerative colitis is characterized by 
inflammation o f intestinal mucosa [Amirshahrokhi et al., 2011; Ha et al., 2012; 
Hassan and Soliman, 2010]. It is considered as an autoimmune disease that affects 
mainly the colorectal region o f the gastrointestinal tract [Ha et al., 2012; Hassan and 
Soliman, 2010]. The main clinical symptoms o f ulcerative colitis are diarrhea, 
mucilage or blood-pus stools and abdominal pain [Gong et al., 2012; Ramadass et al.,
2013]. The ulcerative colitis is a long known medical condition that affects mainly the 
western population [Oosegi et al., 2008; Ramadass et al., 2013; Thippeswamy et al., 
2011]. Recent data indicates that significantly high rates o f  disease contraction occur 
among Asians with rising statistics over the years [Onishi et al., 2008; Ramadass et 
al., 2013]
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